Adverse Event reporting information can be found in footer

Request a Meeting


The only licensed treatment for idiopathic nocturnal polyuria in adults (including the over 65s)*1

  • Noqdirna is a low-dose desmopressin melt formulation.1 The melt formulation of desmopressin has been shown to have a longer duration of action than the tablet.2
  • Noqdirna is the only licensed medication indicated for adult patients with bothersome nocturia due to nocturnal polyuria including patients over the age of 65.*1

Studies show Noqdirna may be a valuable add-on treatment to bladder outlet obstruction (BOO) and overactive bladder (OAB) therapy in cases where nocturia persists despite treatment3,4

nogdina sub stripe image

For adults with bothersome nocturia due to idiopathic nocturnal polyuria – whatever their age or gender

  • Nocturnal polyuria – often the underlying cause of nocturia10

  • Noqdirna – proven to reduce bothersome night time voiding7,8

  • The only licensed medication for the treatment of nocturnal polyuria including the over 65s1



*Scottish Medicines Consortium (SMC) advice: desmopressin oral lyophilisate (Noqdirna®) is accepted for restricted use within NHS Scotland. Indication under review: Symptomatic treatment of nocturia due to idiopathic nocturnal polyuria in adults. SMC restriction: For use in patients aged 65 years and over. Two Phase Ill, placebo-controlled studies demonstrated that desmopressin, at licensed doses over three months, significantly reduced the mean number of nocturnal voids and resulted in higher proportions of responders compared to placebo, in patients with nocturia.5


*All Wales Medicines Strategy Group (AWMSG) advice: Desmopressin acetate (Noqdirna®) for the treatment of nocturia due to idiopathic nocturnal polyuria in adults is recommended for restricted use within NHS Wales. Desmopressin acetate (Noqdirna®) should be restricted for use in the following subpopulation within its licensed indication for the treatment of nocturia due to idiopathic nocturnal polyuria in adults: aged over 65, for whom treatment options are currently limited. Desmopressin acetate (Noqdirna®) is not recommended for use within NHS Wales outside of this subpopulation.6


Patients over 65 should be monitored for sodium at treatment initiation, 4-8 days after treatment initiation and at one month to reduce risk of hyponatraemia. Noqdirna should be discontinued if the serum sodium level falls below the lower limit of the normal range (ie 135 mmol/L).1


†The Noqdirna Summary of Product Characteristics (SmPC) does not recommend co-administration with other therapies.1



Noqdirna: Reduces noctural urine volume7,8


*Treatment contrast / odds ratio -83.56 (95% CI: -138.74, -28.38). †Treatment contrast/odds ratio -83.56 (95% Cl:5.7, -19.9). Placebo = Standard of care Including lifestyle modifications



Noqdirna: Increases time to first void allowing for better sleep quality7,8



*Treatment contrast / odds ratio 49.03 (95% CI: 16.35, 81.70). †Treatment contrast / odds ratio 39.0 (es% Cl: 11.0, 66.9). Placebo = Standard of care Including lifestyle modifications



Noqdirna demonstrated the ability to increase time to first void by an average of 39-49 minutes at month 3 vs placebo,7,8 further resulting in a mean total initial undisturbed sleep period of approximately 4.5 hours at 3 months in one treatment group, significantly improving patient quality of life.8


Noqdirna: Improves quality of life7-9


Statistically significant difference vs. placebo, repeated measures ANCOVA ps0.05



Noqdirna is well-tolerated with the added benefit of reduced patient activity impairment7,8

The use of Noqdirna in patients with nocturnal polyuria has been shown to be well-tolerated in both male and female patients.7,8 Patient-reported outcomes demonstrated statistically significant reduction (p=0.03) in ctivity impairment compared to the placebo group.7 *Noqdirna, a low-dose desmopressin with gender-based dosing, reduces the risk of serious adverse events such as hyponatraemia.1 Click here to access a guide to managing your patients with idiopathic nocturnal polyuria and hyponatraemia.



*Noqdirna contraindications include hypersensitivity of the active substances or to any of the excipients, habitual or psychogenic polydipsia (resulting in a urine production exceeding 40 mVkg/24 hours), known or suspected cardiac insufficiency or other conditions associated with fluid overload, sufficient to require treatment with diuretics (including history of such conditions), moderate and severe renal insufficiency (creatinine clearance below 50 ml/min), known history of hyponatraemia and syndrome of inappropriate antidiuretic hormone (ADH) secretion (SIADH).1


  1. Noqdirna Summary of Product Characteristics. May 2016. Available at: Date accessed: September 2017.
  2. De Guchtenaere A, et al. J Urol 2011;185:2308–2313.
  3. Kim JC et al. J Urol 2017;197(2):459–464.
  4. Rovner ES et al. Low Urin Tract Symptoms 2017 May 31. [Epub ahead of print].
  5. Scottish Medicines Consortium. Desmopressin (Noqdirna). August 2017. Available at: Date accessed: September 2017.
  6. All Wales Medicines Strategy Group . Desmopressin (Noqdirna). October 2017. Available at:  Date accessed: November 2017.
  7. Sand PK et al. J Urol 2013;190:958–964.
  8. Weiss JP et al. J Urol 2013;190:965–972.
  9. Samsa G et al. Pharmacoeconomics 1999;15(2):141–155.
  10. Weiss JP et al. J Urol 2011;186:1358–1363.

Job Code: UK-NOQD-2000015 - Date of preparation: January 2023


Our use of cookies

We use cookies (including third party cookies) to collect data while you use this website in order to make it work, keep it secure and comply with regulations. We’d also like your consent to use cookies so we can provide you with tailored content and advertising and analyse how you and other people use the website.

Select “On” to consent to our use of these cookies and continue to the website, or select “Off” to control which types of cookies we use. You can read more about cookies in our Privacy Policy.

Necessary cookies

Necessary cookies enable core functionality such as security, network management, and accessibility. You may disable these by changing your browser settings, but this may affect how the website functions.

Analytics cookies

We’d like to set Google Analytics cookies to help us to improve our website by collecting and reporting information on how you use it. The cookies collect information in away that does not directly identify anyone. For more information on how these cookies work, please see our Privacy Policy.